Roderick Wong
Roderick Wong's purchase track record
Roderick Wong has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/24/2023 | OBIO | $18.09M | +41.3% | -32.5% | +13.7% |
| 7/22/2022 | OBIO | $10.01M | -0.7% | +0.5% | +0.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
OBIO Shares Rise 5.2% Amid Positive Momentum. Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.
Transaction History
| RCKT | ▲ Buy | Grant | 27,832 | $0 | 6/18/2026 | View on chart |
| RCKT | ▲ Buy | Grant | 30,000 | $0 | 6/18/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 17,667 | $0 | 6/18/2025 | View on chart |
| OBIO | ▲ Buy | Open Market | 1,808,512 | $18.1M | 1/24/2023 | View on chart |
| OBIO | ▲ Buy | Open Market | 1,000,000 | $10.0M | 7/22/2022 | View on chart |
| RCKT | ▲ Buy | Grant | 812,516 | $26.4M | 8/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.